Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
84 hedge funds and large institutions have $109M invested in Sorrento Therapeutics, Inc. in 2019 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 12 closing their positions.
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
45% more capital invested
Capital invested by funds: $75.1M → $109M (+$33.9M)
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
23% more call options, than puts
Call options by funds: $2.45M | Put options by funds: $1.98M
8% more funds holding
Funds holding: 78 → 84 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.08M |
| 2 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$805K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$740K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$734K |
| 5 |
AMG
Advisors Management Group
La Crosse,
Wisconsin
|
+$520K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$10.3M |
| 2 |
Morgan Stanley
New York
|
-$5.39M |
| 3 |
Citigroup
New York
|
-$2.22M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.17M |
| 5 |
Renaissance Technologies
New York
|
-$1.94M |
SRNE Hedge Fund Activity: Q1 2019 in Review
84 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q1 2019, worth a combined $109M — up 45% from $75.1M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SRNE positions and 12 closed out — a net gain of 6 holders — while 28 added to existing stakes and 22 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.08M. The largest seller was State Street, cutting an estimated $10.3M.
- 84 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q1 2019, up from 78 in Q4 2018.
- Funds reported $109M of Sorrento Therapeutics, Inc. stock for Q1 2019, up 45% quarter-over-quarter.
- 18 funds opened new Sorrento Therapeutics, Inc. positions in Q1 2019 and 12 closed out, a net change of +6 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q1 2019 was Vanguard Group, an estimated $2.08M added.
- The largest Sorrento Therapeutics, Inc. seller in Q1 2019 was State Street, an estimated $10.3M sold.
Based on aggregated 13F filings for Q1 2019.